Elevated TAGLN2 expression has been frequently observed across multiple malignancies, including bladder cancer (24), pancreatic cancer (25), colorectal cancer (26), renal cell carcinoma (27), esophageal cancer (28), cholangiocarcinoma (28), and gastric cancer (29), and is associated with enhanced tumor cell proliferation, invasion, metastasis, and epithelial-mesenchymal transition (EMT). Here, TAGLN2 is linked to cholangiocarcinoma.